Serum PAF-acetylhydrolase (PAF-AH) in Hepatobiliary Disease.
|
Accession number;03A0059366
|
| Title;Serum PAF-acetylhydrolase (PAF-AH) in Hepatobiliary Disease. |
| Author;
ITO TADASHI
(Osakatetsudobyoin Hokenkanribu)
SHIKATA USHIO
(Osakatetsudobyoin Hokenkanribu)
OMI HAJIME
(Osakatetsudobyoin Hokenkanribu)
TSUJIMOTO TAKASHI
(Nishi-Nihon Ryokaku Tetsudo, Osaka Tetsudo Byoin)
WATANABE MOTOKI
(Nishi-Nihon Ryokaku Tetsudo, Osaka Tetsudo Byoin)
KIMOTO KUNIHIKO
(Nishi-Nihon Ryokaku Tetsudo, Osaka Tetsudo Byoin)
KOSAKA TETSUYA
(Azuweru Kenkyukaihatsubu)
TAKAYAMA MASAHARU
(Azuweru Kenkyukaihatsubu)
ADACHI YUKIHIKO
(Miedai I Daisannaika)
|
Journal Title;Japanese Pharmacology & Therapeutics
|
Journal Code:Z0947A
|
ISSN:0386-3603
|
|
VOL.30;NO.Suppl.2;PAGE.S.331-S.334(2002)
|
| Figure&Table&Reference;FIG.4, REF.6 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;An enzyme inactivating the platelet-activating factor (PAF), PAF acetylhydrolase (PAF-AH), has been reported to be involved in various diseases and conditions. However, there have been only a few detailed studies regarding the relationship between hepatic diseases and PAF-AH. We determined the serum PAF-AH activities in the patients with hepatobiliary disease to investigate their relationship. The subjects were 37 inpatients with hepatobiliary disease. The serum PAF-AH activities were determined by a newly developed colorimetric method (AZWELL Auto PAF-AH), and were compared with the activities in 67 healthy subjects. At the same time, the clinical course was monitored. Furthermore, association of serum PAF-AH activities with hepatic functions was invetigated. The median value of the serum PAF-AH activities in patients with hepatobiliary disease was 732 IU/L, which was markedly higher than that in the healthy subjects (387 IU/L; p<0.001). While the serum PAF-AH activities correlated with total bilirubin, but did not exhibit any correlation with AST, ALT, ALP, .GAMMA.-GTP or CRP. In many subjects, the serum PAF-AH activity tended to decrease in association with improvement of the disease condition. These findings suggest an association between serum PAF-AH activity and hepatobiliary disease. (author abst.) |
|
|
|
Related Articles;
|
|
